Hormonal IUD: advantages and disadvantages

Among the range of contraceptive options available, the hormonal intrauterine device (IUD) has become one of the most commonly selected long-acting reversible contraceptives (LARC) in recent years. The hormonal IUD is a small, T‑shaped device placed inside the uterine cavity that releases a progestin (levonorgestrel) locally. Depending on the product, it provides effective contraception for multiple years—typically between 3 and 8 years—while offering additional noncontraceptive benefits for many users.

This article provides a comprehensive clinical review of how hormonal IUDs work, the advantages and disadvantages, expected side effects, potential complications, contraindications and eligibility, insertion/removal considerations, and guidance for counseling patients. Information and statistics are aligned with guidance and evidence from major clinical authorities (American College of Obstetricians and Gynecologists [ACOG], National Institutes of Health [NIH], Mayo Clinic, Cleveland Clinic).

Overview: what is a hormonal IUD?

A hormonal IUD is an intrauterine device that contains levonorgestrel, a synthetic progestin. The device is typically T‑shaped and is inserted through the cervix into the uterine cavity by a trained clinician in an outpatient setting. Once in place, the device continuously releases a low dose of levonorgestrel directly into the uterine environment.

Common levonorgestrel IUD products in use include Mirena, Kyleena, Liletta, and Skyla (brand names and approved durations vary by region and regulatory approvals). Different products contain varying amounts of levonorgestrel and are approved for differing durations of use; in general, hormonal IUDs provide effective contraception for approximately 3–8 years depending on the specific device.

(See official clinical resources for current product-specific approvals and durations.) [ACOG; Mayo Clinic; Cleveland Clinic]

How the hormonal IUD works (mechanism of action)

The contraceptive effect of levonorgestrel IUDs is predominantly local and involves several mechanisms:

Endometrial alteration: Local progestin exposure leads to thinning of the endometrial lining, which reduces the likelihood of implantation and makes the uterine environment less receptive to a fertilized egg.
Cervical mucus thickening: Levonorgestrel increases the viscosity of cervical mucus, creating a barrier to sperm transport from the vagina to the uterine cavity.
Sperm and ovum effects: The intrauterine environment becomes less hospitable to sperm, reducing sperm motility and viability.
Ovulation: Systemic absorption of levonorgestrel from the IUD is minimal compared with systemic progestin methods; ovulation is usually preserved in many users, although some devices and some users may experience partial suppression of ovulation.

Because the levonorgestrel IUD acts primarily within the uterus and cervix, systemic hormone levels are generally lower than with oral or implantable systemic progestin contraception. [ACOG; NIH; Mayo Clinic]

Types of hormonal IUDs and duration of effectiveness

Several levonorgestrel IUDs are available, with differences in initial hormone load, monthly release rates, and approved duration of use. Typical examples include:

Mirena: historically approved for 5 years for contraception and more recently approved for longer durations in some indications (check current regulatory labeling). Also used for treatment of heavy menstrual bleeding. [Mayo Clinic; ACOG]
Kyleena: lower hormone load and typically effective for up to 5 years.
Skyla (also called Jaydess in some countries): smaller device with lower hormone content, typically effective for up to 3 years.
Liletta: similar to Mirena in hormone dosing; approved durations may vary by region.

Because approvals and labeling can change, clinicians should verify current manufacturer and regulatory information when counseling patients about specific products. In practice, hormonal IUDs are generally described as long‑acting contraceptives effective for multiple years depending on the device. [Mayo Clinic; ACOG]

Advantages of the hormonal IUD

The hormonal IUD offers several important advantages that make it a preferred option for many individuals seeking long-term reversible contraception:

High effectiveness: Levonorgestrel IUDs are among the most effective contraceptives available, with typical-use failure rates of less than 1% per year, comparable to other LARC methods. This high efficacy is largely independent of user adherence. [ACOG; NIH]
Long-acting and low maintenance: Once inserted, the device provides continuous contraception for years without daily, weekly, or monthly attention.
Rapid return to fertility: Fertility generally returns quickly after removal of the device, with most women able to conceive within the first several months if not using contraception. There is no evidence that levonorgestrel IUDs cause long‑term infertility. [ACOG; NIH]
Reduced menstrual bleeding: Many users experience lighter menstrual bleeding over time; some develop amenorrhea (absence of bleeding) after months of use. The levonorgestrel IUD is an effective medical therapy for heavy menstrual bleeding and can reduce the need for surgical interventions for bleeding. [Mayo Clinic]
Effective for people who cannot take estrogen: Because levonorgestrel IUDs contain only progestin, they are an option for those with contraindications to estrogen-containing methods (for example, those with certain cardiovascular risk factors). [ACOG]
Minimal systemic hormone exposure: Compared with systemic progestin methods (pills, injectables, implants), levonorgestrel IUDs produce lower circulating hormone levels in most users, which may reduce systemic side effects for some individuals. [Mayo Clinic]
Suitable for breastfeeding: Hormonal IUDs are considered compatible with breastfeeding and can be inserted postpartum. They have minimal impact on milk production or infant growth in most studies. [ACOG; NIH]
Immediate reversal: The method is reversible; contraception ends promptly once the device is removed.
Cost-effectiveness: Although upfront insertion costs may be higher than short-acting methods, the long duration of effectiveness makes IUDs cost-effective over time. [Cleveland Clinic; NIH]

Disadvantages and common side effects

Despite the many advantages, hormonal IUDs are not free of disadvantages or potential adverse effects. These should be discussed clearly during counseling.

Irregular bleeding and spotting: The most common early side effect is irregular bleeding or spotting, particularly during the first 3–6 months after insertion. Over time, bleeding generally decreases and many users experience lighter periods or amenorrhea. [ACOG; Mayo Clinic]
Hormonal side effects: Although systemic absorption is low, some users report systemic effects such as headaches, mood changes, acne, breast tenderness, or weight changes. These symptoms typically occur in a minority of users. [Mayo Clinic; Cleveland Clinic]
Cramping and discomfort at insertion: Insertion can cause cramping, pain, and vasovagal symptoms (faintness) in some individuals. These effects are usually short-lived. Analgesics taken prior to the procedure or local anesthesia can be offered to reduce discomfort. [ACOG; Cleveland Clinic]
Expulsion: The device may be expelled from the uterus, usually during the first few months after placement. Expulsion rates vary but are more common in younger users and in immediate postpartum insertion. Partial or complete expulsion requires clinical assessment and potentially replacement. [ACOG]
Uterine perforation: Rarely, the device can perforate the uterine wall during insertion; perforation rates are low (on the order of approximately 1 per 1,000 insertions) but represent a serious complication that may require surgical management. [ACOG; NIH]
Infection risk: The procedure of insertion carries a small, transient increased risk of pelvic infection, primarily related to preexisting sexually transmitted infections (STIs) at the time of insertion. Screening for STIs and treating active infection reduces this risk. PID risk associated with IUD use is highest in the first 20 days after insertion and then returns to baseline. [ACOG; CDC]
Pregnancy while using an IUD: Although rare, pregnancies can occur with an IUD in place. If pregnancy occurs with an IUD in situ, there is an increased relative risk that the pregnancy could be ectopic (located outside the uterine cavity). Prompt evaluation and management are required. [ACOG]
Contraindications related to breast cancer: Because levonorgestrel is a progestin, current or recent diagnosis of breast cancer (a hormone-sensitive malignancy) is generally considered a contraindication to use until oncologic evaluation permits. [ACOG; NIH]
Access and procedural logistics: Insertion and removal require a trained clinician and appropriate clinical settings. Not all clinics provide same-day insertion, and cost or insurance coverage can affect access.

Risks and complications — incidence and clinical implications

Understanding the incidence of risks can aid shared decision-making.

Contraceptive effectiveness: Levonorgestrel IUDs have contraceptive failure rates that are typically quoted at under 1% per year, making them comparable to sterilization in effectiveness but with reversibility. [ACOG; NIH]
Expulsion: Reported expulsion rates vary by study and by patient characteristics (parity, age, timing of insertion). Estimates range broadly from approximately 2% to 10% during the first year; higher rates are observed when inserted immediately postpartum. [ACOG]
Perforation: Clinically significant uterine perforation is uncommon, estimated at about 0.1% (approximately 1 per 1,000 insertions), though reported rates depend on clinician experience, insertion technique, and patient factors. [ACOG; NIH]
Infection: The increase in pelvic inflammatory disease related to IUD insertion is primarily limited to the immediate post-insertion period; long‑term risk of PID due to the device itself is low if there is no ongoing STI exposure. [CDC; ACOG]
Ectopic pregnancy: While overall pregnancy risk is low with an IUD, if a pregnancy occurs it has a higher likelihood of being ectopic compared with pregnancies in the general population. The absolute risk of ectopic pregnancy with an IUD in place is still low because overall pregnancy rates are low. [ACOG]

These statistics should be presented alongside individualized risk assessment and clinical context during counseling.

Candidate selection and contraindications

Professional guidelines from ACOG and the CDC’s Medical Eligibility Criteria support the broad use of levonorgestrel IUDs across reproductive age groups, including nulliparous individuals and adolescents. However, specific contraindications and cautions include:

Absolute contraindications

Current pregnancy.
Current purulent cervicitis or pelvic inflammatory disease.
Known or suspected uterine or cervical cancer or distortion of the uterine cavity preventing correct placement.
Known hypersensitivity to levonorgestrel or any component of the device.
Current diagnosis or history of breast cancer for which progestin exposure is not advised.

Relative contraindications / caution

Active, untreated sexually transmitted infection (screen and treat before insertion).
Uterine anomalies (e.g., fibroids) that distort the cavity.
Recent postpartum or post‑abortion periods: immediate postpartum insertion is possible but associated with higher expulsion risk; individual counseling is important.
Immunosuppression (individual risk assessment recommended).

Clinicians should conduct a medical history, pelvic examination as indicated, and appropriate STI screening based on risk to ensure safe insertion. [ACOG; CDC; NIH]

Insertion and removal: what to expect clinically

Insertion

Procedure setting: Insertion is typically performed in an outpatient clinic by a trained clinician. The procedure generally takes only a few minutes after preparation.
Timing: The IUD can be inserted at any time in the menstrual cycle if pregnancy has been reasonably excluded. If inserted within the first 7 days of a normal menstrual cycle, the device is considered immediately effective for contraception. If inserted at other times, short-term backup contraception or abstinence is recommended for 7 days. (Refer to current guidelines for device-specific timing.) [ACOG; CDC]
Pain management: Many clinicians offer oral analgesia (e.g., NSAIDs) before insertion and techniques such as cervical anesthesia or paracervical block when indicated. Cervical dilation is not usually required with most IUDs.
Post‑insertion: Patients commonly experience cramping and light bleeding or spotting for a short period. Most return to routine activities within 24 hours.

Removal

The device is removed by a clinician using gentle traction on the retrieval strings; removal is usually quick and can be done in the clinic. If the strings are not visible or removal is difficult, ultrasound guidance or hysteroscopic removal may be needed.
Contraceptive effect ends immediately at removal; individuals wishing to avoid pregnancy should arrange alternative contraception before removal unless planning conception.

Immediate postpartum insertion and postabortion insertion

Insertion immediately after delivery or after pregnancy termination is possible and provides effective contraception; however, immediate postpartum insertion is associated with an increased risk of expulsion compared with delayed insertion. Clinicians should discuss timing and individual factors with patients. [ACOG]

Bleeding patterns and management

Early months: Irregular bleeding and spotting are common in the initial months after insertion. This is a frequent reason for early discontinuation among some users.
Long-term pattern: Over time, most users experience lighter periods, decreased menstrual cramps, and in some cases amenorrhea. The levonorgestrel IUD is also an evidence-based treatment for heavy menstrual bleeding, often reducing menstrual blood loss significantly.
Management of irregular bleeding: Counseling that irregular bleeding is common and often improves with time is essential. If bleeding is persistent or bothersome, clinicians may consider short courses of combined oral contraceptives, NSAIDs, or tranexamic acid for management in selected cases, after evaluating underlying causes. [Mayo Clinic; ACOG]

Fertility after removal

Evidence indicates that fertility returns rapidly after removal of the levonorgestrel IUD. Most individuals who wish to conceive will do so within several months. There is no consistent evidence that prior use of a hormonal IUD negatively affects long‑term fertility. If conception does not occur within a reasonable timeframe after device removal, standard fertility evaluation should proceed as clinically indicated. [ACOG; NIH]

Use during breastfeeding

Levonorgestrel IUDs are considered compatible with breastfeeding. Systemic exposure to levonorgestrel from an IUD is low, and available evidence does not indicate adverse effects on milk production or infant growth. Insertion timing postpartum may consider individual needs: immediate postpartum insertion is an option for women desiring contraception before discharge, but clinicians should counsel about higher expulsion risk. Many clinicians place IUDs at the 4–6 week postpartum visit as an alternative. [ACOG; NIH]

Comparison with other contraceptives

Versus copper IUD: The copper IUD does not contain hormones and is a good option for patients who prefer nonhormonal contraception. Copper IUDs may cause heavier menstrual bleeding and increased cramping, whereas hormonal IUDs commonly reduce bleeding and cramping. Both offer high contraceptive efficacy. [Mayo Clinic; ACOG]
Versus progestin implants: Both implants and intrauterine levonorgestrel provide long-acting reversible contraception. Implants release systemic progestin and often alter ovulation more consistently; they may be associated with systemic side effects such as mood changes or weight gain in some users. Choice depends on patient preference for systemic versus local hormone exposure and bleeding pattern considerations. [ACOG]
Versus combined hormonal methods: Combined oral contraceptives require daily adherence and contain estrogen, which may be contraindicated in some patients. Levonorgestrel IUDs avoid systemic estrogen exposure and reduce adherence burden. [ACOG]

Counseling and shared decision-making

Effective contraceptive counseling should be patient-centered, addressing the individual’s reproductive goals, medical history, bleeding preferences, and tolerance for potential adverse effects. Key points to review include:

Effectiveness and duration of the chosen device.
Expected bleeding patterns over time and management options.
Risks and complications including expulsion, perforation (rare), and infection risk around insertion.
Timing of insertion and whether backup contraception is needed.
Return to fertility after removal.
Cost, insurance coverage, and availability of insertion and removal services.
Alternatives and comparison with other contraceptive methods.

Documentation of informed consent and provision of anticipatory guidance (e.g., when to seek care for severe pain, fever, signs of pregnancy, or missing strings) is important.

Myths and frequently asked questions

Will an IUD cause infertility? No. There is no evidence that properly placed levonorgestrel IUDs cause long-term infertility. Fertility generally returns shortly after removal. [ACOG; NIH]
Can the IUD “move” to other organs? Uterine perforation at insertion is rare. When perforation occurs, the device may penetrate the uterine wall and potentially enter the abdominal cavity; this is an uncommon complication and typically requires surgical management. Regular follow-up and immediate evaluation if severe pain occurs after insertion help mitigate risks. [ACOG]
Does an IUD cause sexually transmitted infections (STIs)? An IUD does not cause STIs. However, placing an IUD in the presence of an untreated STI can increase the risk of pelvic infection. Clinicians usually screen for STIs and treat as indicated prior to insertion in persons at increased risk. [CDC; ACOG]
Can I get pregnant immediately after removal? Yes. Contraception ends at removal and conception can occur soon after; patients desiring pregnancy after removal do not typically experience significant delays in returning fertility. [ACOG; NIH]

Clinical scenarios and special considerations

Adolescents and nulliparous individuals: Professional bodies support the use of levonorgestrel IUDs in adolescent and nulliparous populations as a safe and appropriate contraceptive option when desired. Counseling should address bleeding expectations and dispel myths about infertility. [ACOG]
Recent childbirth or termination of pregnancy: Immediate postpartum or postabortion insertion is feasible and can be appropriate when access to follow-up is uncertain; clinicians should counsel regarding increased expulsion rates with immediate postpartum insertion compared with delayed insertion. [ACOG]
Women with heavy menstrual bleeding: The levonorgestrel IUD is an effective therapeutic option for heavy menstrual bleeding and may reduce the need for surgical interventions such as hysterectomy. [Mayo Clinic; ACOG]

When to seek medical attention

After IUD insertion, patients should seek prompt medical attention if they experience:

Severe or persistent pelvic pain.
Fever or unusual vaginal discharge suggesting infection.
Heavy bleeding that is new and persistent.
Suspected pregnancy or inability to feel IUD strings.
Signs of allergic reaction.

Prompt evaluation can identify complications (displacement, expulsion, infection, pregnancy) and guide appropriate management.

Summary and clinical conclusion

Levonorgestrel‑releasing intrauterine devices are highly effective, long‑acting, reversible contraceptives with the added benefits of decreased menstrual bleeding and utility in people who cannot take estrogen. They are suitable for a wide range of reproductive-aged individuals, including adolescents and those who have not had children. The main disadvantages are early irregular bleeding and the small risks associated with an invasive insertion procedure (expulsion, perforation, infection). Appropriate patient selection, informed counseling about expected bleeding patterns and side effects, and attention to insertion technique and STI screening optimize outcomes and patient satisfaction.

Shared decision-making between clinician and patient—taking into account medical history, reproductive goals, preferences regarding bleeding and hormones, and access to services—is essential when considering a hormonal IUD.

References

American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin and Committee Opinions on Intrauterine Devices and Long-Acting Reversible Contraception. https://www.acog.org
National Institutes of Health (NIH) — MedlinePlus: Intrauterine Devices (IUDs). https://medlineplus.gov/intrauterinedevice.html
Mayo Clinic. Intrauterine device (IUD). https://www.mayoclinic.org/tests-procedures/iud/about/pac-20384709
Cleveland Clinic. IUD (Intrauterine Device): Types, Side Effects, and Benefits. https://my.clevelandclinic.org/health/treatments/21906-iud-intrauterine-device
Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use. https://www.cdc.gov/reproductivehealth/contraception/mmwr/index.htm

(For device-specific approvals and labeling, consult current manufacturer information and local regulatory guidance.)